دورية أكاديمية
Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association.
| العنوان: | Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association. |
|---|---|
| المؤلفون: | Tai CG; IQVIA Real-World Solutions, Durham, North Carolina, USA., Haviland MJ; IQVIA Real-World Solutions, Durham, North Carolina, USA., Kissler SM; Harvard University T.H. Chan School of Public Health, Boston, Massachusetts, USA., Lucia RM; IQVIA Real-World Solutions, Durham, North Carolina, USA., Merson M; Duke University Duke Global Health Institute, Durham, North Carolina, USA., Maragakis LL; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Ho DD; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA., Anderson DJ; Duke University Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA., DiFiori J; National Basketball Association, New York, New York, USA.; Hospital for Special Surgery, New York, New York, USA., Grubaugh ND; Yale University School of Public Health, New Haven, Connecticut, USA., Grad YH; Harvard University T.H. Chan School of Public Health, Boston, Massachusetts, USA., Mack CD; IQVIA Real-World Solutions, Durham, North Carolina, USA. |
| المصدر: | Journal of medical virology [J Med Virol] 2024 Mar; Vol. 96 (3), pp. e29505. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , Basketball* , Vaccines*, Humans ; Male ; Female ; SARS-CoV-2 ; Antibodies, Viral |
| مستخلص: | SARS-CoV-2 antibody levels may serve as a correlate for immunity and could inform optimal booster timing. The relationship between antibody levels and protection from infection was evaluated in vaccinated individuals from the US National Basketball Association who had antibody levels measured at a single time point from September 12, 2021, to December 31, 2021. Cox proportional hazards models were used to estimate the risk of infection within 90 days of serologic testing by antibody level (<250, 250-800, and >800 AU/mL 1 ), adjusting for age, time since last vaccine dose, and history of SARS-CoV-2 infection. Individuals were censored on date of booster receipt. The analytic cohort comprised 2323 individuals and was 78.2% male, 68.1% aged ≤40 years, and 56.4% vaccinated (primary series) with the Pfizer-BioNTech mRNA vaccine. Among the 2248 (96.8%) individuals not yet boosted at antibody testing, 77% completed their primary vaccine series 4-6 months before testing and the median (interquartile range) antibody level was 293.5 (interquartile range: 121.0-740.5) AU/mL. Those with levels <250 AU/mL (adj hazard ratio [HR]: 2.4; 95% confidence interval [CI]: 1.5-3.7) and 250-800 AU/mL (adj HR: 1.5; 95% CI: 0.98-2.4) had greater infection risk compared to those with levels >800 AU/mL. Antibody levels could inform individual COVID-19 risk and booster scheduling. (© 2024 Wiley Periodicals LLC.) |
| References: | Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-1416. doi:10.1016/s0140-6736(21)02183-8. Britton A, Fleming-Dutra KE, Shang N, et al. Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and delta variant predominance. JAMA. 2022;327(11):1032. doi:10.1001/jama.2022.2068. Tai CG, Maragakis LL, Connolly S, et al. Association between COVID-19 booster vaccination and omicron infection in a highly vaccinated cohort of players and staff in the National Basketball Association. JAMA. 2022;328(2):209. doi:10.1001/jama.2022.9479. Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910-1921. doi:10.1056/nejmoa2200674. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421-2430. doi:10.1056/nejmoa2115926. Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern Med. 2022;182(2):179. doi:10.1001/jamainternmed.2021.7382. Grunau B, Goldfarb DM, Asamoah-Boaheng M, et al. Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals. JAMA. 2022;327(3):279. doi:10.1001/jama.2021.21921. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712-1720. doi:10.1056/NEJMoa2201570. US Food and Drug Administration. EUA Authorized Serology Test Performance. Accessed October 31, 2022. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. US Food and Drug Administration. Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication. Accessed November 1, 2022. https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032-2040. doi:10.1038/s41591-021-01540-1. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50. doi:10.1126/science.abm3425. US Food and Drug Administration. LIAISON SARS-CoV-2 TrimericS IgG. Accessed November 4, 2022. https://www.fda.gov/media/149060/download. Perkmann T, Mucher P, Ösze D, et al. Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology. J Clin Virol. 2023;158:105345. doi:10.1016/j.jcv.2022.105345. Lavezzo E, Pacenti M, Manuto L, et al. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Med. 2022;14(1):61. doi:10.1186/s13073-022-01066-2. Bonelli F, Blocki FA, Bunnell T, et al. Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021;59(8):1463-1467. doi:10.1515/cclm-2021-0023. Perkmann T, Perkmann-Nagele N, Koller T, et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr. 2021;9(1):e00247-21. doi:10.1128/Spectrum.00247-21. Mack CD, Tai C, Sikka R, et al. Severe acute respiratory syndrome coronavirus 2 reinfection: a case series from a 12-month longitudinal occupational cohort. Clin Infect Dis. 2022;74(9):1682-1685. doi:10.1093/cid/ciab738. Mack CD, DiFiori J, Tai CG, et al. SARS-CoV-2 transmission risk among national basketball association players, staff, and vendors exposed to individuals with positive test results after COVID-19 recovery during the 2020 regular and postseason. JAMA Intern Med. 2021;181(7):960. doi:10.1001/jamainternmed.2021.2114. US Food and Drug Administration. LIAISON® SARS-CoV-2 TrimericS IgG (Instructions for Use). Accessed December 19, 2022. https://www.fda.gov/media/149059/download. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676-681. doi:10.1038/s41586-021-04388-0. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-135. doi:10.1038/s41586-021-03398-2. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8. Hay JA, Kissler SM, Fauver JR, et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study. eLife. 2022;11:e81849. doi:10.7554/eLife.81849. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med. 2022;386(6):599-601. doi:10.1056/NEJMc2119641. Yu J, Collier AR, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386(16):1579-1580. doi:10.1056/NEJMc2201849. Springer DN, Perkmann T, Jani CM, et al. Reduced sensitivity of commercial spike-specific antibody assays after primary infection with the SARS-CoV-2 Omicron variant. Microbiol Spectr. 2022;10(5):e02129-22. doi:10.1128/spectrum.02129-22. Kwok SL, Cheng SM, Leung JN, et al. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill. 2022;27(2):2101197. doi:10.2807/1560-7917.ES.2022.27.2.2101197. Shrotri M, Fragaszy E, Nguyen V, et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat Commun. 2022;13(1):5780. doi:10.1038/s41467-022-33550-z. Angel-Korman A, Peres E, Bryk G, et al. Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. Clin Kidney J. 2022;15(2):226-234. doi:10.1093/ckj/sfab206. Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw Open. 2022;5(9):e2231778. doi:10.1001/jamanetworkopen.2022.31778. Hatzakis A, Karabinis A, Roussos S, et al. Modelling SARS-CoV-2 binding antibody waning 8 months after BNT162b2 vaccination. Vaccines. 2022;10(2):285. doi:10.3390/vaccines10020285. Garcia L, Woudenberg T, Rosado J, et al. Kinetics of the SARS-CoV-2 antibody avidity response following infection and vaccination. Viruses. 2022;14(7):1491. doi:10.3390/v14071491. Laing ED, Weiss CD, Samuels EC, et al. Durability of antibody response and frequency of SARS-CoV-2 infection 6 months after COVID-19 vaccination in healthcare workers. Emerg Infect Dis. 2022;28(4):828-832. doi:10.3201/eid2804.212037. Sanchez L, Oviedo Rouco S, Pifano M, et al. Antibody durability at 1 year after Sputnik V vaccination. Lancet Infect Dis. 2022;22(5):589-590. doi:10.1016/S1473-3099(22)00176-1. Pérez-Alós L, Armenteros JJA, Madsen JR, et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022;13(1):1614. doi:10.1038/s41467-022-29225-4. Vicentini C, Zotti CM, Cornio AR, et al. Serological responses up to 9 months following COVID-19 mRNA vaccination in residents and health-care workers of long-term care facilities: a multicenter prospective cohort study in Northern Italy. Vaccines. 2022;10(12):2183. doi:10.3390/vaccines10122183. Rössler A, Knabl L, Raschbichler LM, et al. Reduced sensitivity of antibody tests after omicron infection. Lancet Microbe. 2023;4(1):e10-e11. doi:10.1016/S2666-5247(22)00222-1. US Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines Including Boosters. Accessed November 1, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html. |
| معلومات مُعتمدة: | NBA |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2 antibodies; immunity; serology testing; test utilization |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Vaccines) |
| تواريخ الأحداث: | Date Created: 20240311 Date Completed: 20240312 Latest Revision: 20240312 |
| رمز التحديث: | 20240312 |
| DOI: | 10.1002/jmv.29505 |
| PMID: | 38465748 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.29505 |